Skip to main content

Advertisement

SpringerLink
Log in

Treating the idiopathic nephrotic syndrome: are steroids the answer?

  • Educational Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

The use of steroids in idiopathic nephrotic syndrome is the major discovery of the twentieth century in the field of pediatric nephrology. At onset of the twenty-first century, steroids remain the first line of treatment at first flare. All the protocols to treat the first flare are similar by a common sequence including a first phase of daily prednisolone/prednisone at a dose of 60 mg/m2/day for at least 4 weeks followed by an alternate-day regimen for several weeks. It appears that a cumulated dose of 2240 mg/m2 given in 8 weeks at the first flare without tapering sequence is not inferior to increased dose and duration in terms of prevalence of frequent relapsers and the subsequent cumulated dose of steroids at 24 months of follow-up. A higher cumulated dose might only be interesting in patients aged below 4 years although a formal demonstration is still missing. Several retrospective studies are concordant to suggest that intravenous methylprednisolone pulses are useful to reach a full urinary remission in case of oral resistance to 4 weeks of oral prednisone/prednisolone. A majority of patients have multiple relapses after the treatment of the first flare and half meet the definition of steroid dependency. In those patients, long-lasting alternate-day prednisone/prednisolone therapy does not lead to long-lasting remission, opening the question of the best strategy of immunosuppression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Riley CM (1950) The effect of adrenocorticotrophic hormone on salt and water excretion in children with the nephrotic syndrome. Am J Dis Child 80:520–521

  2. Barnett HL, Mc NH, Mc CW, Forman C, Rapoport M, Michie A, Barbero G (1950) The effects of ACTH and cortisone on the nephrotic syndrome. Am J Dis Child 80:519–520

  3. Luetscher JA Jr, Deming QB (1950) Treatment of nephrosis with cortisone. J Clin Invest 29:1576–1587

    Article  PubMed  PubMed Central  Google Scholar 

  4. Drummond KN, Michael AF, Good RA, Vernier RL (1966) The nephrotic syndrome of childhood: immunologic, clinical, and pathologic correlations. J Clin Invest 45:620–360

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Deschenes G, Vivarelli M, Peruzzi L (2017) Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 176:647–654

    Article  PubMed  Google Scholar 

  6. KDIGO (2012) KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2:139–274

    Article  Google Scholar 

  7. Spencer RL, Chun LE, Hartsock MJ, Woodruff ER (2017) Glucocorticoid hormones are both a major circadian signal and major stress signal: How this shared signal contributes to a dynamic relationship between the circadian and stress systems. Front Neuroendocrinol S0091-3022(17)30103–30106. https://doi.org/10.1016/j.yfrne

  8. Vacchio MS, Ashwell JD (1997) Thymus-derived glucocorticoids regulate antigen-specific positive selection. J Exp Med 185:2033–2038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Purton JF, Monk JA, Liddicoat DR, Kyparissoudis K, Sakkal S, Richardson SJ, Godfrey DI, Cole TJ (2004) Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol 173:3816–3824

    Article  CAS  PubMed  Google Scholar 

  10. Andreau K, Lemaire C, Souvannavong V, Adam A (1998) Induction of apoptosis by dexamethasone in the B cell lineage. Immunopharmacology 40:67–76

    Article  CAS  PubMed  Google Scholar 

  11. Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17:233–247

    Article  CAS  PubMed  Google Scholar 

  12. Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M, Ramonda R, Iaccarino L, Doria A (2011) The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 10:305–310

    Article  CAS  PubMed  Google Scholar 

  13. Pasini A, Aceto G, Ammenti A, Ardissino G, Azzolina V, Bettinelli A, Cama E, Cantatore S, Crisafi A, Conti G, D’Agostino M, Dozza A, Edefonti A, Fede C, Groppali E, Gualeni C, Lavacchini A, Lepore M, Maringhini S, Mariotti P, Materassi M, Mencarelli F, Messina G, Negri A, Piepoli M, Ravaglia F, Simoni S, Spagnoletta L, Montini G, (2015) Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality. Pediatr Nephrol 30:91–101

  14. Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, Kalaivani M, Hari P, Bagga A (2015) Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 87:217–224

    Article  CAS  PubMed  Google Scholar 

  15. Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC, Wetzels JF, van der Heijden AJ, Nauta J (2013) Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 24:149–519

    Article  CAS  PubMed  Google Scholar 

  16. Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Igarashi T, Ohashi Y, Iijima K (2015) A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 87:225–232

    Article  CAS  PubMed  Google Scholar 

  17. Webb N, Wooley R, Bretell E, Cummins C, Trompeter R, Barsoum E, Ives N, investigators P (2017) Standard vs. extended course prednisolone therapy for the presenting episode of steroid sensitive nephrotic syndrome: the PREDNOS study. Pediatr Nephrol 32:1647–1648

    Article  Google Scholar 

  18. Teeninga N, Guan Z, Stevens J, Kist-van Holthe JE, Ackermans MT, van der Heijden AJ, van Schaik RH, van Gelder T, Nauta J (2016) Population pharmacokinetics of prednisolone in relation to clinical outcome in children with nephrotic syndrome. Ther Drug Monit 38:534–545

    Article  CAS  PubMed  Google Scholar 

  19. Ekka BK, Bagga A, Srivastava RN (1997) Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol 11:597–599

    Article  CAS  PubMed  Google Scholar 

  20. Hahn D, Hodson EM, Willis NS, Craig JC (2015) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev, Issue3, Art N° CD001533, 1–130. https://doi.org/10.1002/14651858.CD001533.pub5

  21. Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS (1985) Long-term outcome for children with minimal-change nephrotic syndrome. Lancet 1:368–370

    Article  CAS  PubMed  Google Scholar 

  22. Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M (2003) A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 41:1155–1562

    Article  CAS  PubMed  Google Scholar 

  23. Hoyer PF, Brodeh J (2006) Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 17:1151–1157

    Article  CAS  PubMed  Google Scholar 

  24. Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar N, van den Heuvel L, Schreuder MF (2017) REducing STEroids in relapsing nephrotic syndrome: the RESTERN study—protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. BMJ Open 7:e018148

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. APN (1982) Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 306:451–454

    Article  Google Scholar 

  26. Vivarelli M, Massella L, Ruggiero B, Emma F (2017) Minimal change disease. Clin J Am Soc Nephrol 12:332–345

    Article  CAS  PubMed  Google Scholar 

  27. Broyer M, Kleinknecht C (1978) Traitement des néphroses corticosensibles par la corticothérapie discontinue prolongée. In: Mathieu H (ed) Journée Parisienne de Pédiatrie. Flammarion Médecine Science, Paris, pp 158–710

    Google Scholar 

  28. Srivastava RN, Vasudev AS, Bagga A, Sunderam KR (1992) Long-term, low-dose prednisolone therapy in frequently relapsing nephrotic syndrome. Pediatr Nephrol 6:247–250

    Article  CAS  PubMed  Google Scholar 

  29. Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A (2011) Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:63–69

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Abeyagunawardena AS, Trompeter RS (2008) Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch Dis Child 93:226–228

    Article  CAS  PubMed  Google Scholar 

  31. Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV, Abeyagunawardena S, Illangasekera YA, Karunadasa UI, Trompeter RS (2017) Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome. Pediatr Nephrol 32:1377–1382

    Article  PubMed  Google Scholar 

  32. Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P (1997) A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome. Pediatr Nephrol 11:418–422

    Article  CAS  PubMed  Google Scholar 

  33. Singhal R, Pandit S, Dhawan N (2015) Deflazacort versus prednisolone: randomized controlled trial in treatment of children with idiopathic nephrotic syndrome. Iran J Pediatr 25:e510

    Article  PubMed  PubMed Central  Google Scholar 

  34. Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV (1984) Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int 36:245–252

    Article  CAS  PubMed  Google Scholar 

  35. Foster BJ, Shults J, Zemel BS, Leonard MB (2006) Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 21:973–980

    Article  PubMed  Google Scholar 

  36. Leroy V, Baudouin V, Alberti C, Guest G, Niaudet P, Loirat C, Deschenes G, Czernichow P, Simon D (2009) Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment. Pediatr Nephrol 24:2393–2400

    Article  PubMed  Google Scholar 

  37. Motoyama O, Iitaka K (2007) Final height in children with steroid-sensitive nephrotic syndrome. Pediatr Int 49:623–625

    Article  PubMed  Google Scholar 

  38. Simmonds J, Grundy N, Trompeter R, Tullus K (2010) Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child 95:146–149

    Article  PubMed  Google Scholar 

  39. Kaye LD, Kalenak JW, Price RL, Cunningham R (1993) Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus 30:142–144

    CAS  PubMed  Google Scholar 

  40. Gulati S, Gulati K (2005) Bone disease in nephrotic syndrome—prevention is better than cure. Pediatr Nephrol 20:111–112

    Article  PubMed  Google Scholar 

  41. Ksiazek J, Niemirska A, Lipka M, Grenda R (2006) Evaluation of arterial intima-media thickness (IMT) in children with idiopathic nephrotic syndrome—preliminary report. Przegl Lek 63(Suppl 3):205–207

    PubMed  Google Scholar 

  42. Zajaczkowska M, Papierkowski A, Szczepanowska A, Zinkiewicz Z, Borzecka H, Zbaranska S (2001) Influence of glucocorticoid steroid therapy on gastric and duodenal mucosa and helicobacter pylori infection in children with nephrotic syndrome. Pol Merkur Lekarski 10:165–167

    CAS  PubMed  Google Scholar 

  43. Upadhyay A, Mishra OP, Prasad R, Upadhyay SK, Schaefer F (2016) Behavioural abnormalities in children with new-onset nephrotic syndrome receiving corticosteroid therapy: results of a prospective longitudinal study. Pediatr Nephrol 31:233–238

    Article  PubMed  Google Scholar 

  44. Ulinski T, Carlier-Legris A, Schlecht D, Ranchin B, Cochat P (2005) Triamcinolone acetonide: a new management of noncompliance in nephrotic children. Pediatr Nephrol 20:759–762

    Article  PubMed  Google Scholar 

  45. Dehoux L, Hogan J, Dossier C, Fila M, Niel O, Maisin A, Macher MA, Kwon T, Baudouin V, Deschênes G (2016) Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome. Pediatr Nephrol 31:2095–2101

    Article  PubMed  Google Scholar 

  46. Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, Maternik M, Massella L, Emma F, Niaudet P, Cornelissen EAM, Schurmans T, Raes A, van de Walle J, van Dyck M, Gulati A, Bagga A, Davin JC (2018) A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney Int 93:510–518

    Article  CAS  PubMed  Google Scholar 

  47. Kuzma-Mroczkowska E, Skrzypczyk P, Panczyk-Tomaszewska M (2016) Levamisole therapy in children with frequently relapsing and steroid-dependent nephrotic syndrome: a single-center experience. Cent Eur J Immunol 41:243–247

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Baudouin V, Alberti C, Lapeyraque AL, Bensman A, Andre JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschenes G, Jacqz-Aigrain E, Loirat C (2012) Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol 27:389–396

    Article  PubMed  Google Scholar 

  49. Mahmoud I, Basuni F, Sabry A, El-Husseini A, Hassan N, Ahmad NS, Elbaz M, Moustafa F, Sobh M (2005) Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 20:735–472

    Article  PubMed  Google Scholar 

  50. Kengne-Wafo S, Massella L, Diomedi-Camassei F, Gianviti A, Vivarelli M, Greco M, Stringini GR, Emma F (2009) Risk factors for cyclosporin a nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol 4:1409–1416

    Article  CAS  PubMed  Google Scholar 

  51. Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, Loirat C, Deschenes G, Baudouin V (2011) Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 26:927–932

    Article  PubMed  Google Scholar 

  52. Zagury A, de Oliveira AL, de Moraes CA, de Araujo Montalvao JA, Novaes RH, de Sa VM, Monteiro de Carvalho DB, Matuck T (2011) Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol 26:915–920

    Article  PubMed  Google Scholar 

  53. Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32:2071–2078

    Article  PubMed  Google Scholar 

  54. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guerin V, Lapillonne H, Deschenes G, Ulinski T (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood—follow-up after CD19 recovery. Nephrol Dial Transplant 27:1083–1089

    Article  CAS  PubMed  Google Scholar 

  55. Hari P, Bagga A, Mantan M (2004) Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr 41:993–1000

    PubMed  Google Scholar 

  56. Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ (2010) Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol 25:899–903

    Article  PubMed  Google Scholar 

  57. Zhang H, Wang Z, Dong LQ, Guo YN (2016) Children with steroid-resistant nephrotic syndrome: long-term outcomes of sequential steroid therapy. Biomed Environ Sci 29:650–655

    CAS  PubMed  Google Scholar 

  58. Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J (2007) Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 22:2183–2193

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Nephrology, APHP Robert-Debré, Sorbonne Paris Cité University, 48 Bd Sérurier, F-75019, Paris, France

    Georges Deschênes, Claire Dossier & Julien Hogan

Authors
  1. Georges Deschênes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claire Dossier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julien Hogan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georges Deschênes.

Ethics declarations

Conflict of interest

Georges Deschênes declares that he has no conflict of interest in the field of the paper. Claire Dossier and Julien Hogan received a grant from Délégation de la Recherche Clinique for randomized control trials in patients with Idiopathic Nephrotic Syndrome (PHRCI-15-015 and PHRCN-16-0547, respectively).

Additional information

Answers

1. b; 2. c; 3. b, c, d, e; 4. a, d; 5. d

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deschênes, G., Dossier, C. & Hogan, J. Treating the idiopathic nephrotic syndrome: are steroids the answer?. Pediatr Nephrol 34, 777–785 (2019). https://doi.org/10.1007/s00467-018-3963-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-018-3963-x

Keywords

Search

Navigation